Publications by authors named "P Mandima"
Article Synopsis
- Introduction of long-acting injectable cabotegravir (CAB-LA) for HIV prevention showed effectiveness, and this study examines its safety and pharmacokinetics in pregnant women participating in the HPTN 084 trial during a blinded period.
- In the study, pregnant participants were divided into two groups receiving either CAB-LA or TDF/FTC, with careful monitoring of pregnancy outcomes and maternal adverse events, finding that there was no significant difference in adverse event rates or poor pregnancy outcomes between the two groups.
- The analysis revealed a total of 57 confirmed pregnancies over 3845 person-years, with 81% resulting in live births, and the study concluded that CAB-LA did not result in significantly different safety or outcomes
Article Synopsis
- - This analysis focused on postpartum women undergoing HIV treatment to explore the prevalence and risk factors for neurocognitive toxicity, particularly in relation to the interaction between Isoniazid Preventive Therapy (IPT) and Efavirenz.
- - Involving 956 women, the study evaluated depression, cognitive function, sleep quality, and peripheral neuropathy at various postpartum weeks, revealing peaks of mild depression (13%), cognitive complaints (8%), and poor sleep quality (10%) at 12 weeks.
- - Results indicated no significant differences in neurotoxic symptom odds based on the timing of IPT initiation or use of Efavirenz, suggesting the need for further investigation into neurotoxicity risk factors.
Background: The success of prevention of mother to child transmission of HIV (PMTCT) programs dependents on pregnant women accessing antenatal care (ANC) services. Failure to access ANC throughout the course of pregnancy presents a missed opportunity to fully utilize PMTCT services and a high risk for vertical HIV transmission. Whilst not booking for ANC was about 6% in Zimbabwe, according to the 2015 Zimbabwe Demographic and Health Survey, it is important to determine the local burden of pregnant women both un-booked for ANC and living with HIV.
View Article and Find Full Text PDFBackground: Oral pre-exposure prophylaxis has been introduced in more than 70 countries, including many in sub-Saharan Africa, but women experience considerable barriers to daily pill-taking, such as stigma, judgement, and the fear of violence. Safe and effective long-acting agents for HIV prevention are needed for women. We aimed to evaluate the safety and efficacy of injectable cabotegravir compared with daily oral tenofovir diphosphate plus emtricitabine (TDF-FTC) for HIV prevention in HIV-uninfected women.
View Article and Find Full Text PDFBackground: Given well documented challenges faced by pregnant women living with HIV taking lifetime ART, it is critical to understand the impact of short-term ART exposure followed by treatment interruption on maternal health outcomes.
Methods: HIV+ breastfeeding (BF) and Formula Feeding (FF) women with CD4 counts > 350 cells/mm3, enrolled in the 1077BF/1077FF PROMISE trial were followed to assess the effect of ART during pregnancy and breastfeeding respectively. The first analysis compared ART use limited to the antepartum period (AP-only) relative to women randomized to Zidovudine.